Abstract
Patient selection criteria are very similar to that of LDR implants; there are fewer differences in the list of preoperative investigations and more in patient selection for both combined HDR and external beam treatment and HDR monotherapy. Recommendations for necessary equipment, interdisciplinary team, dose prescription, treatment documentation, and quality control are given.
New trends and investigational methods (focal therapy, salvage treatments) are discussed including the role of antiandrogen treatments.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen GW, Howard AR, Jarrad DF et al (2007) Management of prostate cancer recurrences after radiation therapy – brachytherapy as a salvage option. Cancer 110:1405–1416
Ash D, Flynn A, Battermann J et al (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57:315–321
Bertermann H, Brix F (1990) Ultrasonically guided interstitial high dose rate brachytherapy with Ir-192: technique and preliminary results in locally confined prostate cancer. In: Martinez AA, Orton CF, Mould RF (eds) Brachytherapy HDR and LDR: remote afterloading state of the art. Nucletron International BV, Leersum, pp 281–303
Bolla M, Gonsales D, Warde P et al (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295–300
Borghede G, Hedelin H, Holmang S et al (1997) Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 44:237–244
De la Rosette JJMCH, Wink MH, Mamoulakis C et al (2009) Optimization of prostate cancer detection in a clinical population: results from an eight versus 12-core transrectal ultrasound guided biopsy protocol. J Urol 182(4):1329
De la Rosette JJMCH, Ahmed HJ, Barentsz J, Barentsz T (2010) Focal therapy in prostate cancer—report from a consensus panel. J Endourol 24(5):775–780
Demanes DJ, Rodrigues RR, Altieri GA (2000) High dose rate prostate brachytherapy: the California endocurietherapy (CET) method. Radiother Oncol 57:289–296
Demanes DJ, Gilhezan M, Schour L et al (2007) High dose rate brachytherapy (HDR-BT) as monotherapy for favorable prostate cancer: excellent 5-year control rates and low toxicity. Int J Radiat Oncol Biol Phys 69:S83
Dinges S, Deger S, Koswig S et al (1998) High dose rate interstitial brachytherapy combined with external beam irradiation for localized prostate cancer—a prospective study. Radiother Oncol 48:197–203
Egevad L, Granfors T, Karlberg L et al (2002) Prognostic value of the Gleason score in prostate cancer. BJU Int 89(6):538–542
Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol 59:61–71
Hinkelbein W (1998) Adjuvant or therapeutic androgen suppression in locoregional advanced prostatic carcinoma (RTOG 85–31) [Article in German]. Strahlenther Onkol 174:385–386
Hoskin P, Rojas A, Lowe G et al (2011) High-dose-rate brachytherapy alone for localized prostate cancer in patients at a moderate or high risk of biochemical recurrence. J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2011.04.031
http://cancer.beaumont.edu/beaumont-launches-prostate-cancer-study-single-dose-radiation-treatment. Accessed 25 Aug 2011
ICRU Report 58 (1997) Dose and volume specification for reporting interstitial brachytherapy, International Commission on Radiation Units and Measurements, ICRU, Bethesda
Kovács G, Galalae R, Wirth B et al (1995) Optimization of interstitial brachytherapy by a new implant technique in the treatment of prostate cancer (ger). Strahlenther Onkol 171:685–688
Kovács G, Pötter R, Loch T et al (2005) GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localized prostate cancer. Radiother Oncol 74:137–148
Kovács G, Melchert C, Sommerauer M et al (2007) Intensity modulated high-dose-rate brachytherapy boost complementary to external beam radiation for intermediate- and high-risk localized prostate cancer patients – how we do it in Luebeck/Germany. Brachytherapy 6:142–148
Krauss D, Kestin L, Ye H et al (2011) Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 80(4):1064–1071
Kronz JD, Milord R, Wilentz R, Weir EG, Schreiner SR, Epstein JI (2003) Lesions missed on prostate biopsies in cases sent in for consultation. Prostate 54(4):310–314
Lawton CA, Winter K, Murray K et al (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937–946
Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67(4):1106–1112
Mark RJ, Akins RS, Anderson PJ et al (2007) Interstitial high dose rate (HDR) brachytherapy as monotherapy for early stage prostate cancer: a report of 206 cases. Int J Radiat Oncol Biol Phys 69:S329
Martinez AA, Gonzalez J, Stromberg J et al (1995) Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 33:1019–1027
Martinez AA, Demanes J, Vargas C et al (2010) High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33:481–488
Polascik TJ, Mouraviev V (2008) Focal therapy for prostate cancer. Curr Opin Urol 18:269
Salambier C, Lavagnini P, Nickers P et al (2007) Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 83:3–10
Vicini FA, Martinez AA, Hanks G et al (2002) An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 95:2126–2135
Vicini FA, Shah C, Kestin L et al (2011) Identifying differences between biochemical failure and cure: incidence rates and predictors. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2011.05.017
Wallner K (2002) Prostate brachytherapy under local anesthesia: lessons from the first 600 patients. Brachytherapy 1:145–148
Watanabe H, Igari D, Tanahasi Y et al (1974) Development and application of new equipment for transrectal ultrasonography. J Clin Ultrasound 2:91–98
Yoshioka Y, Konishi K, Oh RJ et al (2006) High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 80:62–68
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kovács, G. (2013). Patient Selection and Recommendations: HDR. In: Kovács, G., Hoskin, P. (eds) Interstitial Prostate Brachytherapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-36499-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-36499-0_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-36498-3
Online ISBN: 978-3-642-36499-0
eBook Packages: MedicineMedicine (R0)